Original reporting and analysis on the stories shaping biotech.
Genentech axed 103 scientists from its storied research unit and signed a $490 million breast cancer deal with Astex on virtually the same timeline. It's the clearest signal yet of how big pharma is reshuffling the R&D deck in 2026.
A gene editing startup co-founded by a Nobel laureate just filed to go public, and it's not chasing rare diseases. Scribe Therapeutics wants to use CRISPR to replace your daily cholesterol pills with a single dose that silences the genes behind heart disease.
Novartis dropped $1.1 billion upfront on a UK biotech with zero human data, marking its boldest entry into the red-hot ADC space. The bet: a completely novel payload class that could leapfrog every antibody-drug conjugate on the market today.
For 40 years, the only treatment for alpha-1 antitrypsin deficiency has been weekly IV infusions of the same protein. Now Sanofi and Wave Life Sciences are racing toward fundamentally different solutions, and both just dropped data that suggest the drought is finally ending.
Nine pharma giants just signed pricing deals with the Trump administration, trading deep drug discounts for three-year tariff protection. Wall Street loved it. But the real story isn't about today's prices; it's about the negotiating framework being built for tomorrow.
Regeneron just dropped $2.3 billion on a company that started in a rented lab corner with an $8 curtain protecting its equipment. Parabilis Medicines isn't building traditional ADCs; it's engineering spy-like peptides that slip inside cells and neutralize "undruggable" cancer targets from within.
Roche's experimental KRAS inhibitor divarasib just beat both Amgen's and BMS's approved drugs in a direct phase 3 showdown, hitting survival endpoints that could reshape the entire KRAS lung cancer market. It's the biotech equivalent of challenging two champions to a fight at the same time and walking away with both belts.
Immunovant's FcRn inhibitor failed two Phase 3 trials in thyroid eye disease, costing $39 million to shut down. The failure isn't just one company's problem; it's exposing the limits of an entire drug class that Wall Street thought could conquer all of autoimmunity.
Eli Lilly dropped $202 million on a preclinical startup with zero drugs in trials. The reason? A protein that smuggles DNA past your immune system and could make gene therapy repeatable for the first time.
The Novo Nordisk Foundation just made its largest donation ever: $861 million over a decade to turn Denmark's BioInnovation Institute into a European biotech powerhouse. The catch? It's not just about drugs anymore.
BioMarin closed its $270 million Inozyme acquisition on July 1st. Five days later, the drug failed its key Phase 3 bone-healing endpoint despite hitting its biochemical target. The ultra-rare disease bet just got a lot riskier.
Regeneron's fianlimab combo showed five extra months of progression-free survival versus Keytruda in melanoma, but missed statistical significance by a hair. Wall Street wiped 11% off the stock and analysts are calling it a worst-case scenario for the company's oncology ambitions.
BioNTech is quietly shopping three German manufacturing sites built during the pandemic's peak, cutting 1,860 jobs in its biggest restructuring ever. The mRNA giant is betting its future on cancer, not COVID, but the pivot comes with serious risks.
A federal judge blocked Colorado's first-ever state price cap on Amgen's Enbrel, ruling that capping the price of a patented drug likely violates federal law. The decision could freeze similar efforts in a dozen other states.
Anthropic launched Claude Science, an AI research workbench that connects to 60+ scientific databases and promises to compress years of pharma R&D into days. But there's a catch: the company also wants to discover its own drugs, putting it in direct competition with the customers it's courting.
Roche launched its AXELIOS 1 gene sequencer, pricing genomes at $150 and taking direct aim at Illumina's decade-long grip on the sequencing market. With 13 years of failed attempts behind it, Roche's comeback is backed by new chemistry, heavyweight partnerships, and pricing that could reshape genomic medicine.
Two Nature papers unveil a CAR-T therapy that kills solid tumors and the immune cells protecting them, with the first human patient showing six months of disease control and zero serious side effects. GPNMB might be the solid-tumor target the field has been searching for.
Valneva pulled the world's only chikungunya vaccine from the U.S. after FDA suspension, safety deaths, and dismal sales. With the disease surging globally, the withdrawal exposes a painful truth about tropical disease vaccines and the market's refusal to support them.
Sandoz just got FDA acceptance for generic versions of Eli Lilly's blockbuster weight-loss drug tirzepatide, setting up a long-game challenge to the $100 billion GLP-1 market. Patents keep the launch years away, but the world's biggest generics maker is already plotting price cuts that could reshape who gets access to obesity treatment.
Zymeworks, an oncology biotech known for its HER2-targeting cancer drugs, just dropped $929 million to buy a COPD lung treatment. The financing structure is clever, the strategic logic is surprisingly sound, and the real test comes in August.
For six years, Tepezza was the only FDA-approved drug for thyroid eye disease, generating nearly $2 billion in annual sales with zero competition. Viridian Therapeutics just changed that with the approval of Lumvoa, and the monopoly's days are officially numbered.
A drug that flopped in lupus and MS just posted blockbuster kidney disease data, and the FDA decision is days away. Atacicept's unlikely redemption arc could reshape the IgA nephropathy market.
Join thousands of biotech professionals who start their day with our free, daily briefing.